HC Wainwright Reiterates "Buy" Rating for Sana Biotechnology (NASDAQ:SANA)

HC Wainwright reissued their buy rating on shares of Sana Biotechnology (NASDAQ:SANA - Free Report) in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a $11.00 target price on the stock. HC Wainwright also issued estimates for Sana Biotechnology's Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at ($0.59) EPS.

Several other equities research analysts have also recently weighed in on SANA. TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research report on Wednesday, January 8th. Jefferies Financial Group assumed coverage on shares of Sana Biotechnology in a research report on Friday, March 14th. They set a "buy" rating and a $7.00 price target for the company. Finally, Citizens Jmp upgraded shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $10.80.

Remove Ads

Sana Biotechnology Stock Performance

Shares of NASDAQ:SANA traded up $0.05 during midday trading on Tuesday, reaching $2.31. 4,923,605 shares of the company's stock were exchanged, compared to its average volume of 3,051,681. The company's 50 day simple moving average is $2.95 and its two-hundred day simple moving average is $3.16. The firm has a market capitalization of $519.81 million, a PE ratio of -1.65 and a beta of 1.63. Sana Biotechnology has a 12 month low of $1.52 and a 12 month high of $10.50.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. On average, research analysts anticipate that Sana Biotechnology will post -1.16 earnings per share for the current year.

Insider Buying and Selling at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares of the company's stock, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 31.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SANA. FMR LLC lifted its stake in Sana Biotechnology by 16.3% in the third quarter. FMR LLC now owns 31,609,175 shares of the company's stock valued at $131,494,000 after buying an additional 4,438,949 shares in the last quarter. Boxer Capital Management LLC bought a new stake in shares of Sana Biotechnology in the fourth quarter worth $2,518,000. Corient Private Wealth LLC lifted its position in shares of Sana Biotechnology by 161.7% in the fourth quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company's stock worth $1,928,000 after purchasing an additional 730,699 shares in the last quarter. Millennium Management LLC lifted its position in shares of Sana Biotechnology by 604.8% in the fourth quarter. Millennium Management LLC now owns 728,901 shares of the company's stock worth $1,188,000 after purchasing an additional 625,481 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Sana Biotechnology by 44.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company's stock worth $2,538,000 after purchasing an additional 478,596 shares in the last quarter. Institutional investors own 88.23% of the company's stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.